MAC-545496

Catalog No.S6771 Batch:S677101

Technical Data

Formula	C₁₈H₁₈ClN₅O₃S
Molecular Weight	419.89	CAS No.	838810-96-1
Solubility (25°C)*	In vitro	DMSO	84 mg/mL (200.05 mM)
		Water	˂1 mg/mL
		Ethanol	˂1 mg/mL
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

MAC-545496 is a nanomolar glycopeptide-resistance-associated protein R(GraR) inhibitor with strong binding affinity to the full-length GraR protein (Kd ≤ 0.1 nM). MAC-545496 can reverse β-lactam resistance in methicillin-resistant strains and synergize with CAMPs. MAC-545496 shows remarkable activity in macrophages and attenuates S. aureus virulence in a G. mellonella larvae infection model.

Targets

GraR ^[1]
(Cell-free assay)

0.1 nM(Kd)

In vitro

MAC-545496 shows inhibition of mprF expression in a concentration-dependent manner; the half-maximal inhibitory concentration (IC50) is 0.0376 µg/mL—matching with the concentration range of the synergistic effect with cefuroxime. MAC-545496 only inhibits the citrate-induced biofilm formation in the wild type in a concentration-dependent manner, suggesting additional potential as a lead for drug discovery. Treatment of S. aureus-infected macrophages with different doses of MAC-545496 added 30 min after phagocytosis shows that the MAC-545496 halts S. aureus replication within macrophages starting at 0.5 µg/mL.^[1].

In vivo

MAC-545496 activity is evidenced by increased survival of the drug-treated larvae as compared to infected untreated ones. This corresponds to concentration-dependent killing of S. aureus in the hemolymph of the larvae observed from the CFUs recovered from the hemolymph 200 min after infection. This matchs with the attenuated virulence of the graR::Tn mutant relative to the wild type in Galleria. Treatment with MAC-545496 recapitulates the phenotype of ΔgraR and ΔgraS mutants, effectively inhibiting intracellular S. aureus growth.^[1].

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines RAW macrophages Concentrations 20 µg/mL Incubation Time 12 h Method Stationary-phase cells are washed and diluted in serum-free RPMI (SF-RPMI) and used for infection of RAW macrophages at a multiplicity of infection of ten. One set of replicates for S. aureus USA300 contains MAC-545496 (20 µg/mL) so that the drug is present throughout every step of the experiment. Macrophages exposed to bacteria are centrifuged at 277g to synchronize infection and after 30 min at 37 °C in 5% CO₂, the medium is replaced with SF-RPMI containing gentamicin (100 µg/mL) for 1 h. Here, after phagocytosis, another set of S. aureus USA300 replicates are exposed to MAC-545496 along with gentamicin so that the drug is added after the bacteria are phagocytosed. For wells already treated with MAC-545496, the drug is added too. After gentamicin treatment, one set of wells are lysed by treatment with 0.5 ml of 0.1% Triton X-100 after washing with PBS. The remaining well for each infection is incubated with RPMI containing 5% (vol/vol) non-heat-inactivated FBS until 12 h after infection when the cells are lysed.
Animal Study:^{^[1]}	Animal Models Galleria mellonella larvae Dosages 10 µL/100 mg Administration IV

Cell Assay:^{^[1]}

Cell lines
RAW macrophages
Concentrations
20 µg/mL
Incubation Time
12 h
Method
Stationary-phase cells are washed and diluted in serum-free RPMI (SF-RPMI) and used for infection of RAW macrophages at a multiplicity of infection of ten. One set of replicates for S. aureus USA300 contains MAC-545496 (20 µg/mL) so that the drug is present throughout every step of the experiment. Macrophages exposed to bacteria are centrifuged at 277g to synchronize infection and after 30 min at 37 °C in 5% CO₂, the medium is replaced with SF-RPMI containing gentamicin (100 µg/mL) for 1 h. Here, after phagocytosis, another set of S. aureus USA300 replicates are exposed to MAC-545496 along with gentamicin so that the drug is added after the bacteria are phagocytosed. For wells already treated with MAC-545496, the drug is added too. After gentamicin treatment, one set of wells are lysed by treatment with 0.5 ml of 0.1% Triton X-100 after washing with PBS. The remaining well for each infection is incubated with RPMI containing 5% (vol/vol) non-heat-inactivated FBS until 12 h after infection when the cells are lysed.

Animal Study:^{^[1]}

Animal Models
Galleria mellonella larvae
Dosages
10 µL/100 mg
Administration
IV

References

[1] El-Halfawy OM, et al. Nat Chem Biol. 2020;16(2):143-149.

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.